MX370342B - Preparaciones solidas que contienen tofogliflozina y proceso para producir las mismas. - Google Patents

Preparaciones solidas que contienen tofogliflozina y proceso para producir las mismas.

Info

Publication number
MX370342B
MX370342B MX2016008527A MX2016008527A MX370342B MX 370342 B MX370342 B MX 370342B MX 2016008527 A MX2016008527 A MX 2016008527A MX 2016008527 A MX2016008527 A MX 2016008527A MX 370342 B MX370342 B MX 370342B
Authority
MX
Mexico
Prior art keywords
tofogliflozin
solid preparation
producing same
tablet
powder mixture
Prior art date
Application number
MX2016008527A
Other languages
English (en)
Other versions
MX2016008527A (es
Inventor
Tomoaki Hirayama
Yoshimura Shiho
Wada Kenta
Sakai Kenichi
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Publication of MX2016008527A publication Critical patent/MX2016008527A/es
Publication of MX370342B publication Critical patent/MX370342B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención proporciona un método para producir una composición farmacéutica que es una tableta y que contiene tofogliflozina como un ingrediente activo; el método comprende mezclar un aditivo y tofogliflozina para preparar una mezcla en polvo y obtener una tableta de la mezcla en polvo por compresión directa; el aditivo comprende al menos un relleno.
MX2016008527A 2013-12-27 2014-12-26 Preparaciones solidas que contienen tofogliflozina y proceso para producir las mismas. MX370342B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2013273060 2013-12-27
PCT/JP2014/084561 WO2015099139A1 (ja) 2013-12-27 2014-12-26 トホグリフロジンを含有する固形製剤及びその製造方法

Publications (2)

Publication Number Publication Date
MX2016008527A MX2016008527A (es) 2016-09-13
MX370342B true MX370342B (es) 2019-12-10

Family

ID=53478978

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2019008865A MX390480B (es) 2013-12-27 2014-12-26 Preparaciones solidas que contienen tofogliflozina y proceso para producir las mismas.
MX2016008527A MX370342B (es) 2013-12-27 2014-12-26 Preparaciones solidas que contienen tofogliflozina y proceso para producir las mismas.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2019008865A MX390480B (es) 2013-12-27 2014-12-26 Preparaciones solidas que contienen tofogliflozina y proceso para producir las mismas.

Country Status (21)

Country Link
US (2) US10231930B2 (es)
EP (2) EP3482748A1 (es)
JP (6) JP6513030B2 (es)
KR (2) KR20210082557A (es)
CN (2) CN113058038B (es)
AU (1) AU2014370847B2 (es)
BR (1) BR112016013164B1 (es)
CA (1) CA2934832C (es)
DK (1) DK3087989T3 (es)
ES (1) ES2704065T3 (es)
HR (1) HRP20182199T1 (es)
HU (1) HUE041983T2 (es)
LT (1) LT3087989T (es)
MX (2) MX390480B (es)
PL (1) PL3087989T3 (es)
PT (1) PT3087989T (es)
RU (1) RU2700164C2 (es)
SI (1) SI3087989T1 (es)
TR (1) TR201821042T4 (es)
TW (2) TWI774159B (es)
WO (1) WO2015099139A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7776905B2 (en) 2006-04-07 2010-08-17 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
ES2704065T3 (es) * 2013-12-27 2019-03-14 Chugai Pharmaceutical Co Ltd Preparaciones sólidas que comprenden tofogliflozina y método para su producción
CN108640958B (zh) * 2017-05-05 2021-03-30 镇江圣安医药有限公司 异苯并呋喃衍生物、其药物组合物和制剂以及用途
CN107811983A (zh) * 2017-12-04 2018-03-20 威海贯标信息科技有限公司 一种托格列净组合物
CN107759649A (zh) * 2017-12-12 2018-03-06 威海贯标信息科技有限公司 一种托格列净新晶型
JP2022146628A (ja) * 2021-03-22 2022-10-05 旭化成株式会社 錠剤及びその製造方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS56145214A (en) 1980-04-11 1981-11-11 Taiho Yakuhin Kogyo Kk Ubidecarenone tablet
JP2626975B2 (ja) 1987-03-30 1997-07-02 エーザイ株式会社 低融点油性物質含有錠剤
ES2082723B1 (es) 1994-07-20 1996-10-01 Lilly Sa Formulacion farmaceutica de fluoxetina en forma dispersable.
JPH10287561A (ja) 1997-04-11 1998-10-27 Taisho Pharmaceut Co Ltd イブプロフェン配合固形製剤及びその製造方法
JP2000239185A (ja) 1999-02-16 2000-09-05 Taisho Pharmaceut Co Ltd 医薬組成物
AU2004238253B2 (en) 2003-05-06 2011-01-27 Nostrum Pharmaceuticals, Inc. Controlled release formulation of erythromycin derivatives
JP2005104934A (ja) 2003-10-01 2005-04-21 Eisai Co Ltd 新規組成物及びその製造方法
JP4997741B2 (ja) 2004-11-12 2012-08-08 大正製薬株式会社 低融点薬物含有粉粒体及びその製造方法
TW200637869A (en) * 2005-01-28 2006-11-01 Chugai Pharmaceutical Co Ltd The spiroketal derivatives and the use as therapeutical agent for diabetes of the same
AR065809A1 (es) * 2007-03-22 2009-07-01 Bristol Myers Squibb Co Formulaciones farmaceuticas que contienen un inhibidor sglt2
JP4072195B2 (ja) 2007-10-18 2008-04-09 キッセイ薬品工業株式会社 速放性経口医薬組成物
TW201011043A (en) * 2008-06-20 2010-03-16 Chugai Pharmaceutical Co Ltd Crystal of spiroketal derivatives and process for preparation of spiroketal derivatives
MX345494B (es) * 2009-02-13 2017-02-02 Boehringer Ingelheim Int Gmbh * Composición farmacéutica que comprende derivados de glucopiranosil difenilmetano, dosificación farmacéutica de la misma, procesos para su preparación y usos de la misma para el control glucemico mejorado en un paciente.
US20130035281A1 (en) * 2011-02-09 2013-02-07 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
JP6294665B2 (ja) 2011-02-25 2018-03-14 中外製薬株式会社 スピロケタール誘導体の結晶
EA201301354A1 (ru) 2011-06-03 2014-05-30 Бёрингер Ингельхайм Интернациональ Гмбх Ингибиторы sglt-2, предназначенные для лечения метаболических нарушений у пациентов, леченных нейролептиками
EP4245765A3 (en) * 2013-04-04 2024-03-20 Boehringer Ingelheim Vetmedica GmbH Treatment of metabolic disorders in equine animals
ES2704065T3 (es) * 2013-12-27 2019-03-14 Chugai Pharmaceutical Co Ltd Preparaciones sólidas que comprenden tofogliflozina y método para su producción

Also Published As

Publication number Publication date
JP6759390B2 (ja) 2020-09-23
CA2934832C (en) 2022-03-15
US10231930B2 (en) 2019-03-19
JP2026016750A (ja) 2026-02-03
TW202126311A (zh) 2021-07-16
HRP20182199T1 (hr) 2019-02-22
TW201609194A (zh) 2016-03-16
US20190151248A1 (en) 2019-05-23
EP3087989A1 (en) 2016-11-02
JP2019112424A (ja) 2019-07-11
KR102395687B1 (ko) 2022-05-06
MX2016008527A (es) 2016-09-13
DK3087989T3 (en) 2019-03-25
CN113058038A (zh) 2021-07-02
EP3087989B1 (en) 2018-12-19
MX2019008865A (es) 2019-09-13
BR112016013164B1 (pt) 2022-07-26
RU2016130602A (ru) 2018-02-01
AU2014370847A1 (en) 2016-06-16
CA2934832A1 (en) 2015-07-02
EP3087989A4 (en) 2017-09-20
LT3087989T (lt) 2019-02-11
PL3087989T3 (pl) 2019-07-31
MX390480B (es) 2025-03-20
HUE041983T2 (hu) 2019-06-28
CN105828826B (zh) 2021-04-06
US20160324786A1 (en) 2016-11-10
EP3482748A1 (en) 2019-05-15
RU2016130602A3 (es) 2018-06-08
JP6513030B2 (ja) 2019-05-15
BR112016013164A2 (es) 2017-08-08
JP2024063140A (ja) 2024-05-10
KR20160101719A (ko) 2016-08-25
TWI715523B (zh) 2021-01-11
PT3087989T (pt) 2019-02-26
CN113058038B (zh) 2024-01-12
AU2014370847B2 (en) 2020-02-20
CN105828826A (zh) 2016-08-03
RU2700164C2 (ru) 2019-09-13
HK1224221A1 (zh) 2017-08-18
SI3087989T1 (sl) 2019-03-29
JP2022116267A (ja) 2022-08-09
WO2015099139A1 (ja) 2015-07-02
JPWO2015099139A1 (ja) 2017-03-23
ES2704065T3 (es) 2019-03-14
JP2020203918A (ja) 2020-12-24
KR20210082557A (ko) 2021-07-05
TR201821042T4 (tr) 2019-01-21
US10398653B2 (en) 2019-09-03
TWI774159B (zh) 2022-08-11

Similar Documents

Publication Publication Date Title
MX2015013247A (es) Formulacion de acetato de abiraterona.
PH12016500043A1 (en) Dry powder formulation comprising an anticholinergic, a corticosteroid and a beta-andrenergic for administration by inhalation
MX2017004975A (es) Composiciones de anticuerpos anti-il-7r.
MX2016008527A (es) Preparaciones solidas que contienen tofogliflozina y proceso para producir las mismas.
GEP20176804B (en) Novel indolizine derivatives, method for the production thereof and pharmaceutical compositions containing same
UA116889C2 (uk) Фармацевтична композиція, що містить суміш ізоформ apg101 (cd95-fc)
MD20170048A2 (ro) Formulare pe bază de acetat de abirateronă şi procedee de utilizare a acesteia
EP4282272A3 (en) Method of delivering an agriculturally active ingredient
MX2018000515A (es) Compuestos fluorados de cbd, composiciones y usos de los mismos.
WO2014137797A3 (en) Stable glucokinase activator compositions
IN2013MU03641A (es)
MX363530B (es) Compuesto de benzoxaborol tricíclico, método de preparación y uso del mismo.
MX2015011536A (es) Nuevos antagonistas de receptores trpa1 de sulfamidas.
MX2016001422A (es) Composicion farmaceutica de fingolimod.
MX2015000179A (es) Composiciones y formas de dosificacion de itraconazol y metodos de uso de las mismas.
PH12016502544B1 (en) Pharmaceutical preparation containing entecavir as active ingredient, and preparation method therefor
MX2015016603A (es) Composiciones de corticosteroides.
PH12016501045A1 (en) Method for preparing dry powder inhalation compositions
MX367773B (es) Forma salina sólida de la alfa-6-mpeg6-o-hidroxicodona como agonistas opioides y sus usos.
PH12019500024A1 (en) Pharmaceutical compositions
WO2014122671A3 (en) Solid oral compositions of saxagliptin
IN2014DN07897A (es)
WO2014115168A3 (en) Novel solvate forms of cabazitaxel and process for preparation thereof
EA201692456A1 (ru) Способ получения составов для ингаляции
IN2013CH05440A (es)

Legal Events

Date Code Title Description
FG Grant or registration